KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to 13.32%.

  • Charles River Laboratories International's EBITDA Margin rose 16900.0% to 13.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.5%, marking a year-over-year decrease of 95000.0%. This contributed to the annual value of 5.61% for FY2024, which is 93300.0% down from last year.
  • According to the latest figures from Q3 2025, Charles River Laboratories International's EBITDA Margin is 13.32%, which was up 16900.0% from 9.7% recorded in Q2 2025.
  • Charles River Laboratories International's EBITDA Margin's 5-year high stood at 19.26% during Q2 2022, with a 5-year trough of 16.73% in Q4 2024.
  • For the 5-year period, Charles River Laboratories International's EBITDA Margin averaged around 12.88%, with its median value being 14.89% (2022).
  • As far as peak fluctuations go, Charles River Laboratories International's EBITDA Margin surged by 42200bps in 2022, and later crashed by -298400bps in 2024.
  • Quarter analysis of 5 years shows Charles River Laboratories International's EBITDA Margin stood at 19.09% in 2021, then fell by -22bps to 14.89% in 2022, then fell by -12bps to 13.12% in 2023, then tumbled by -228bps to 16.73% in 2024, then skyrocketed by 180bps to 13.32% in 2025.
  • Its EBITDA Margin stands at 13.32% for Q3 2025, versus 9.7% for Q2 2025 and 7.59% for Q1 2025.